This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
PROfound
VISION Trial
mHSPC
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
CORE-001
CS-003
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Shilpa Gupta, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Decipher Genomic Classifier
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
CRPC with Bone Metastases
Rana R. McKay, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
PSMA-Targeted Therapy
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular Cancer
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
CLARIFY
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
Masofaniten (EPI-7386)
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SECuRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
WCET 2024
BCAN TT 2024
SNMMI 2024
ASCO 2024
AUA 2024
All Conferences
View All
PCF
UroToday Home
Conference Highlights
ASCO 2021
ASCO 2021
Prostate Cancer
Bladder Cancer
Kidney Cancer
Testicular and Penile Cancer
Press Releases
ASCO 2021 Kidney Cancer
Viewing 1-20 of 48 articles
ASCO 2021: Systemic Therapy Considerations After Immunotherapy Combination or Monotherapy in Advanced Renal Cell Carcinoma
ASCO 2021: Sequencing Therapies in Advanced Kidney Cancer in the Contemporary Era – Integration of Multimodality Treatment in Advanced Kidney Cancer: The Roles of Surgery and Radiation Therapy
ASCO 2021: Sequencing Therapies in Advanced Kidney Cancer in the Contemporary Era – Integration of Multimodality Treatment in Advanced Kidney Cancer: Novel Therapeutics on the Horizon in Advanced Kidney Cancer
ASCO 2021: Clinical Activity of Durvalumab and Savolitinib in Met-Driven, Metastatic Papillary Renal Cancer
ASCO 2021: Randomized Phase Ib Study To Evaluate Safety, Pharmacokinetics and Therapeutic Activity of Simlukafusp α in Combination With Atezolizumab ± Bevacizumab in Patients With Unresectable Advanced/ Metastatic Renal Cell Carcinoma (Rcc) (NCT03063762)
ASCO 2021: Making Strides in the Treatment of Non-Clear Cell Carcinoma: Are We Ready for Adaptive and Biomarker-Driven Strategies?
ASCO 2021: Pembrolizumab (Pembro) plus Axitinib (Axi) Versus Sunitinib as First-Line Therapy for Advanced Clear Cell Renal Cell Carcinoma (ccRCC): Results from 42-Month Follow-up of KEYNOTE-426
ASCO 2021: Real-World Outcomes in Patients with Metastatic Clear Cell Renal Cell Carcinoma Receiving Front-Line Axitinib plus Pembrolizumab Versus Ipilimumab plus Nivolumab
ASCO 2021: Vorolanib, Everolimus, and the Combination in Patients with Pretreated Metastatic Renal Cell Carcinoma (CONCEPT Study): A Randomized, Phase 3, Double-Blind, Multicenter Trial
ASCO 2021: CANTATA: Primary Analysis of a Global, Randomized, Placebo-Controlled, Double-Blind Trial of Telaglenastat (CB-839) + Cabozantinib Versus Placebo + Cabozantinib in Advanced/Metastatic Renal Cell Carcinoma Patients on Immune Checkpoint Inhibitor
ASCO 2021: Expanding VEGF Blockade Combination Therapeutic Options in Advanced Renal Cell Carcinoma
ASCO 2021: Health-Related Quality-of-Life (HRQoL) Analysis from the Phase 3 CLEAR Trial of Lenvatinib plus Pembrolizumab or Everolimus Versus Sunitinib for Patients with Advanced Renal Cell Carcinoma (aRCC).
ASCO 2021: Phase II Trial of Durvalumab Plus Tremelimumab With Concurrent Radiotherapy in Patients With Localized Muscle-Invasive Bladder Cancer Treated With a Selective Bladder Preservation Approach: IMMUNOPRESERVE-SOGUG Trial
ASCO 2021: Pembrolizumab Versus Placebo As Post-Nephrectomy Adjuvant Therapy for Patients With Renal Cell Carcinoma: Randomized, Double-Blind, Phase III Keynote-564 Study
ASCO 2021: Analysis of the CLEAR Study in Patients with Advanced Renal Cell Carcinoma (RCC): Depth of Response and Efficacy for Selected Subgroups in the Lenvatinib (LEN) + Pembrolizumab (PEMBRO) and Sunitinib (SUN) Treatment Arms
ASCO 2021: Ipilimumab + Nivolumab in People with Rare Variant Renal Cell Carcinoma Refractory to Nivolumab Alone: Part 2 of UNISON (ANZUP 1602) Nivolumab Then Ipilimumab + Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma
ASCO 2021: Efficacy of Avelumab + Axitinib (A + Ax) Versus Sunitinib (S) by IMDC Risk Group in Advanced Renal Cell Carcinoma (aRCC): Extended Follow-up Results from JAVELIN Renal 101
ASCO 2021: First Results of a Randomized Phase IB Study Comparing Nivolumab/ipilimumab with or Without CBM-588 in Patients with Metastatic Renal Cell Carcinoma
ASCO 2021: Post Hoc Analysis of the CLEAR Study in Advanced Renal Cell Carcinoma (RCC): Effect of Subsequent Therapy on Survival Outcomes in the Lenvatinib (LEN) + Everolimus (EVE) Versus Sunitinib (SUN) Treatment Arms
ASCO 2021: A Phase 2 Single-Arm Study of Cabozantinib in Patients with Advanced or Unresectable Renal Cell Carcinoma Pretreated with One Immune Checkpoint Inhibitor: The BREAKPOINT Trial (MeetUro Trial 03-NCT03463681)
1
2
3
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free